I-MAB SPONS.ADS/1 -0001 - Asset Resilience Ratio
I-MAB SPONS.ADS/1 -0001 (0VY) has an Asset Resilience Ratio of 0.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read I-MAB SPONS.ADS/1 -0001 balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how I-MAB SPONS.ADS/1 -0001's Asset Resilience Ratio has changed over time. See I-MAB SPONS.ADS/1 -0001 (0VY) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down I-MAB SPONS.ADS/1 -0001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 0VY stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €210.00K | 0.08% |
| Total Liquid Assets | €210.00K | 0.08% |
Asset Resilience Insights
- Limited Liquidity: I-MAB SPONS.ADS/1 -0001 maintains only 0.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
I-MAB SPONS.ADS/1 -0001 Industry Peers by Asset Resilience Ratio
Compare I-MAB SPONS.ADS/1 -0001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
|
Jade Biosciences, Inc.
NASDAQ:JBIO |
Biotechnology | 80.21% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for I-MAB SPONS.ADS/1 -0001 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for I-MAB SPONS.ADS/1 -0001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.08% | €210.00K ≈ $245.51K |
€260.52 Million ≈ $304.58 Million |
-49.35pp |
| 2024-12-31 | 49.43% | €105.14 Million ≈ $122.91 Million |
€212.68 Million ≈ $248.65 Million |
+43.95pp |
| 2023-12-31 | 5.48% | €20.22 Million ≈ $23.64 Million |
€368.92 Million ≈ $431.31 Million |
-0.30pp |
| 2022-12-31 | 5.78% | €34.12 Million ≈ $39.89 Million |
€590.45 Million ≈ $690.29 Million |
-7.67pp |
| 2021-12-31 | 13.45% | €118.16 Million ≈ $138.14 Million |
€878.74 Million ≈ $1.03 Billion |
-- |
About I-MAB SPONS.ADS/1 -0001
NovaBridge Biosciences, a biotechnology company, focuses on the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. It is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; VIS-101, a bispecific antibody, which … Read more